Filter by Category: In Vitro Activity
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404
Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone.
Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone. by Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D and Jones RN published in J. Clin. Microbiol. 2018; 56 (8): e00339
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-397
Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide
Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-645
In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe
In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-453
In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016
In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016. Lead author: MD Huband, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-601
In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes.
In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. by Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (8): e00313
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017).
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017). Lead author: LR Duncan, presented at the 28th European Congress of Clinical Microbiology and Infections Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1808
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017).
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1806